Quick Answer
Altimmune, Inc. reported Total Revenue of $41.0 thousand for fiscal year 2025.
Altimmune, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $41.0K +105.0% |
$20.0K -95.3% |
$426.0K +726.5% |
-$68.0K -101.5% |
$4.41M -46.1% |
$8.19M +41.1% |
| Revenue (ASC 606) | — | — | — | — | $4.41M -46.1% |
$8.19M +41.1% |
| Net Income | -$88.09M +7.3% |
-$95.06M -7.5% |
-$88.45M -4.4% |
-$84.71M +12.7% |
-$97.09M -98.0% |
-$49.04M -139.0% |
| Diluted EPS | -$1.00 +25.4% |
-$1.34 +19.3% |
-$1.66 +8.3% |
-$1.81 +23.0% |
-$2.35 -23.0% |
-$1.91 |
| Total Assets | $279.93M +100.9% |
$139.31M -33.9% |
$210.64M +1.8% |
$206.93M -5.5% |
$218.87M -10.7% |
$245.12M +353.4% |
| Cash and Equivalents | $43.76M +18.5% |
$36.93M -72.7% |
$135.12M +21.6% |
$111.10M -41.6% |
$190.30M +64.2% |
$115.92M +1193.3% |
| Long-Term Debt | $34.29M | — | — | — | — | — |
| Stockholders Equity | $224.89M +82.1% |
$123.51M -36.4% |
$194.10M +4.8% |
$185.29M -7.0% |
$199.13M -11.8% |
$225.88M +396.2% |
| R&D Expense | $66.43M -19.2% |
$82.23M +25.0% |
$65.80M -6.7% |
$70.54M -5.4% |
$74.54M +49.8% |
$49.77M +180.2% |
| Operating Income | -$94.49M +8.4% |
-$103.17M -7.6% |
-$95.93M -9.3% |
-$87.74M +9.5% |
-$96.91M -76.9% |
-$54.80M -155.3% |
| Shares Outstanding | 110.88M +53.3% |
72.35M +2.4% |
70.68M +43.7% |
49.20M +20.0% |
40.99M +10.4% |
37.14M +142.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $5.0K | +0.0% | +0.0% |
| Revenue (ASC 606) | September 30, 2022 | $2.0K | -98.7% | -75.0% |
| Net Income | September 30, 2025 | -$19.01M | +16.8% | +14.1% |
| Diluted EPS | September 30, 2025 | -$0.21 | +34.4% | +22.2% |
| Total Assets | September 30, 2025 | $218.45M | +47.7% | +14.8% |
| Cash and Equivalents | September 30, 2025 | $61.24M | +94.6% | -66.6% |
| Long-Term Debt | September 30, 2025 | $14.45M | — | +0.8% |
| Stockholders Equity | September 30, 2025 | $185.60M | +39.2% | +15.0% |
| R&D Expense | September 30, 2025 | $14.96M | -24.5% | -13.2% |
| Operating Income | September 30, 2025 | -$20.86M | +15.8% | +9.0% |
| Shares Outstanding | September 30, 2025 | 95.60M | +34.4% | +12.4% |
- Altimmune, Inc. reported Total Revenue of $41.0 thousand for fiscal year 2025.
- Altimmune, Inc. showed an increase of +105.0% in Total Revenue compared to the prior fiscal year.
- Altimmune, Inc. reported Revenue (ASC 606) of $4.41 million for fiscal year 2021.
- Altimmune, Inc. showed a decrease of -46.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Altimmune, Inc. reported Net Income of -$88.09 million for fiscal year 2025.
- Altimmune, Inc. showed an increase of +7.3% in Net Income compared to the prior fiscal year.
- Altimmune, Inc. reported Diluted EPS of $1.00 per share (loss) for fiscal year 2025.
- Altimmune, Inc. showed an increase of +25.4% in Diluted EPS compared to the prior fiscal year.
- Altimmune, Inc. reported Total Assets of $279.93 million for fiscal year 2025.
- Altimmune, Inc. showed an increase of +100.9% in Total Assets compared to the prior fiscal year.
- Altimmune, Inc. reported Cash and Equivalents of $43.76 million for fiscal year 2025.
- Altimmune, Inc. showed an increase of +18.5% in Cash and Equivalents compared to the prior fiscal year.
- Altimmune, Inc. reported Long-Term Debt of $34.29 million for fiscal year 2025.
- Altimmune, Inc. showed an increase of +4595.1% in Long-Term Debt compared to the prior fiscal year.
- Altimmune, Inc. reported Stockholders Equity of $224.89 million for fiscal year 2025.
- Altimmune, Inc. showed an increase of +82.1% in Stockholders Equity compared to the prior fiscal year.
- Altimmune, Inc. reported R&D Expense of $66.43 million for fiscal year 2025.
- Altimmune, Inc. showed a decrease of -19.2% in R&D Expense compared to the prior fiscal year.
- Altimmune, Inc. reported Operating Income of -$94.49 million for fiscal year 2025.
- Altimmune, Inc. showed an increase of +8.4% in Operating Income compared to the prior fiscal year.
- Altimmune, Inc. reported Shares Outstanding of 110.88 million shares for fiscal year 2025.
- Altimmune, Inc. showed an increase of +53.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: